Liang R, Chiu E, Chan T K, Todd D, Ho F
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Cancer Chemother Pharmacol. 1991;28(2):135-8. doi: 10.1007/BF00689703.
A total of 92 patients with previously untreated intermediate- or high-grade non-Hodgkin's lymphoma attending the University Department of Medicine, Queen Mary Hospital, Hong Kong, were treated with the m-BACOD chemotherapy regimen (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone). Additional involved-field radiotherapy was given to 32 (35%) patients. Myelosuppression was the major toxicity, and 5 (5%) treatment-related deaths occurred due to pneumonia, bleomycin sensitivity, doxorubicin cardiotoxicity and reactivation of hepatitis B infection. The overall complete response (CR) rate was 65/92 (71%) and the relapse rate was 22/65 (34%). The disease-free survival of the 65 CR patients at 2 years was 52% and the overall survival of all 92 patients at 3 years was 56%. The CR rate of stage I and II patients was significantly better than that of those with stage III and IV disease (87% vs 59%; P = 0.01), and the CR rate of stage III patients was superior to that of those with stage IV disease (86% vs 50%; P = 0.05). The overall survival of stage III and IV patients was significantly worse than that of subjects with stage I and II disease (31% vs 73%; P = 0.02). Multivariate analysis revealed that the independent prognostic variables significantly determining the CR rate and survival included the clinical stage and the serum lactate dehydrogenase level. From this study, the results of treatment with the m-BACOD regimen in patients with advance disease appeared to be similar to those obtained using the conventional CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone).
香港玛丽医院大学医学部共收治了92例先前未经治疗的中或高度非霍奇金淋巴瘤患者，采用m-BACOD化疗方案（甲氨蝶呤、博来霉素、阿霉素、环磷酰胺、长春新碱和地塞米松）进行治疗。32例（35%）患者接受了额外的受累野放疗。骨髓抑制是主要毒性反应，5例（5%）患者因肺炎、博来霉素敏感性、阿霉素心脏毒性和乙型肝炎感染再激活而发生与治疗相关的死亡。总体完全缓解（CR）率为65/92（71%），复发率为22/65（34%）。65例CR患者的无病生存率在2年时为52%，92例患者的总生存率在3年时为56%。I期和II期患者的CR率显著高于III期和IV期患者（87%对59%；P=0.01），III期患者的CR率高于IV期患者（86%对50%；P=0.05）。III期和IV期患者的总生存率显著低于I期和II期患者（31%对73%；P=0.02）。多变量分析显示，显著决定CR率和生存率的独立预后变量包括临床分期和血清乳酸脱氢酶水平。从这项研究来看，m-BACOD方案治疗晚期疾病患者的结果似乎与使用传统CHOP方案（环磷酰胺、阿霉素、长春新碱和泼尼松）所获得的结果相似。
